drugset / Trial / NCT03943940
BM-MNCs and UC-MSCs Infusion for Type 2 Diabetes Mellitus Patients
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the preliminary safety and efficacy of autologous bone marrow mononuclear cells (BM-MNCs) and allogeneic umbilical cord tissue-derived mesenchymal stem cells (UC-MSCs) infusion in type 2 Diabetes Mellitus patients.
Timeline
- Start
- 2019-04-24
- Primary completion
- 2019-12-30
- Completion
- 2020-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BM-MNC | Cell therapy | — | Intravenous |
| Subject | human umbilical cord mesenchymal stem cells | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | human umbilical cord mesenchymal stem cells | Cell therapy | 2e+06 cells/kg | Intravenous |